Dr. Brian Thomas Cabaniss, MD

Dr. Cabaniss practices at Emory University Hospital in Atlanta, Georgia, part of Emory University.

Dr. Cabaniss' NPI, 1780998229, was assigned on July 27, 2010. Dr. Cabaniss graduated from Vanderbilt University School Of Medicine in 2010. Dr. Cabaniss' Georgia license number on file is 75965.

Dr. Cabaniss' primary practice is Emory University Hospital, at 1364 Clifton Road, NE, Atlanta, GA 30322 in De Kalb County. The practice phone is (404) 686-8500.

Dr. Cabaniss' primary practice is Emory University Hospital in Atlanta, Georgia, part of Emory University. Dr. Cabaniss is also affiliated with Emory University Hospital Midtown. The medical group on file is Emory Clinic. Dmand AI also links Dr. Cabaniss to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cabaniss practices, 7 sites in all. Vendor and product names are available with a free account.

Epilepsy is Dr. Cabaniss' primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Dr. Cabaniss is board certified in epilepsy by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Cabaniss' licenses on file in 5 states: Georgia, California, North Carolina, Alabama and Missouri.

Dmand AI lists epilepsy and seizures among the conditions Dr. Cabaniss treats.

CMS data shows 421 Medicare services from Dr. Cabaniss across 6 procedure codes in 2024, for 293 Medicare patients. Medicare paid $40,801 for them.

CMS counts 293 Medicare patients who saw Dr. Cabaniss in 2024. The largest group is 65 to 74, with 106 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cabaniss' median patient age at 61, with 54% women.

In 2024, Dr. Cabaniss wrote 1,301 Medicare Part D claims for 221 patients. 80% of them were for generic drugs. CMS names the drug for 1,192 of them, across 27 drugs with 11 or more claims each, at $508,174 in total drug cost. In 2023, CMS named 795 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Cabaniss for performance year 2024, reported through an alternative payment model (APM). Dr. Cabaniss accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cabaniss as offering telehealth.

Dmand AI links 10 papers to Dr. Cabaniss, published from 2018 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Drug Resistant Epilepsy, Electroencephalography and Epilepsy. Dr. Cabaniss has published most often in Epilepsia. Dr. Cabaniss' most frequent co-authors are Abdulrahman Alwaki, MD, Katie Leigh Bullinger and Daniel Louis Drane, PhD.

Dmand AI links Dr. Cabaniss to 1 clinical trial. Conditions studied include Epilepsy, Temporal Lobe and Epilepsies, Partial.

CMS Open Payments shows 5 general payments to Dr. Cabaniss from 2 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. UCB, Inc. paid the most, $385.

Dr. Cabaniss graduated from Vanderbilt University School Of Medicine in 2010.

Dr. Cabaniss is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.